肝胆酸载体和药物诱导的肝毒性
Chitra Saran1, Kim L R Brouwer2
1Transporter Sciences, Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics (PDMB), Merck & Co., Inc., West Point, Pennsylvania, USA.
药物诱导性肝损伤 (DILI) 是一个主要的安全问题. 本综述强调了肝胆酸载体如何影响DILI,讨论了改善药物安全的模型和案例研究.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 药物诱导性肝损伤 (DILI) 是急性肝衰竭的主要原因.
- 改变胆汁酸平衡,涉及肝胆汁酸载体,是一个关键的DILI机制.
- 损坏的输送器可以导致有毒胆酸的积累,增加DILI易感性.
研究的目的:
- 审查肝胆酸载体在DILI中的作用.
- 讨论DILI评估中的当前模型系统和挑战.
- 突出从特定的肝毒药物病例中获得的经验教训.
主要方法:
- 关于肝胆酸运输体和DILI的文献综述.
- 讨论体外模型和计算工具 (例如,DILIsym).
- 分析临床前动物模型挑战和案例研究.
主要成果:
- 肝胆酸运输体在DILI病变发生过程中至关重要.
- 试管和建模工具有助于评估传送器介导的DILI.
- 种类差异对临床前DILI评估构成挑战.
结论:
- 了解传送器角色对于预测和预防DILI至关重要.
- 需要先进的体外模型和生物标志物来可靠地预测DILI.
- 将患者的风险降至最低,需要对药物输送物相互作用进行持续调查.
更多相关视频
08:42Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
Published on: November 27, 2016
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
相关概念视频
Hepatic Drug Clearance: Role of Transporters
Hepatic Drug Excretion: Influencing Factors
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Drug Biotransformation: Overview
Nonlinear Pharmacokinetics: Role of Transporters
Polymorphisms occurring in drug transporters can alter...
